Request Demo
Last update 10 Dec 2025
NK cell therapy (Shenzhen Hank Bioengineering Institute)
Last update 10 Dec 2025
Overview
Basic Info
Drug Type Natural Killer Cell Therapies |
Synonyms HANK cell Shenzhen Hank Bioengineering Institute, Natural killer immunotherapy Shenzhen Hank Bioengineering Institute, NK Immunotherapy(Shenzhen Hank Bioengineering Institute) |
Target- |
Action- |
Mechanism Immunologic cytotoxicity, Natural killer cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
25
Clinical Trials associated with NK cell therapy (Shenzhen Hank Bioengineering Institute)NCT03008343
Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer
NCT03007823
High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma
NCT03008499
High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer
100 Clinical Results associated with NK cell therapy (Shenzhen Hank Bioengineering Institute)
Login to view more data
100 Translational Medicine associated with NK cell therapy (Shenzhen Hank Bioengineering Institute)
Login to view more data
100 Patents (Medical) associated with NK cell therapy (Shenzhen Hank Bioengineering Institute)
Login to view more data
100 Deals associated with NK cell therapy (Shenzhen Hank Bioengineering Institute)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hepatocellular Carcinoma | Phase 2 | China | 01 Dec 2016 | |
| Melanoma | Phase 2 | China | 01 Dec 2016 | |
| Metastatic Colorectal Carcinoma | Phase 2 | China | 01 Dec 2016 | |
| Nasopharyngeal Neoplasms | Phase 2 | China | 01 Dec 2016 | |
| Metastatic Solid Tumor | Phase 2 | China | 01 Aug 2016 | |
| Advanced breast cancer | Phase 2 | China | 01 Jul 2016 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 01 Jul 2016 | |
| B-cell lymphoma recurrent | Phase 2 | China | 01 Jul 2016 | |
| Breast cancer recurrent | Phase 2 | China | 01 Jul 2016 | |
| Laryngeal Neoplasms | Phase 2 | China | 01 Jul 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT02843802 (Pubmed) Manual  | Phase 1/2 | 16 | HANK cells | tzqfvocjwa(jxjxplmhce) = PR , SD , and PD at 3 months after treatment was 18.8%, 50.0% and 31.2% kozaklanki (lrbnpqoyan ) View more | Positive | 04 May 2017 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free